WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012041332) GENETIC VARIATIONS IN THE INTERLEUKIN-6 RECEPTOR GENE AS PREDICTORS OF THE RESPONSE TO TREATMENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/041332    International Application No.:    PCT/DK2011/050373
Publication Date: 05.04.2012 International Filing Date: 30.09.2011
IPC:
C12Q 1/68 (2006.01)
Applicants: RIGSHOSPITALET [DK/DK]; Blegdamsvej 9 DK-2100 København Ø (DK) (For All Designated States Except US).
NIELSEN, Claus Henrik [DK/DK]; (DK) (For US Only).
ENEVOLD, Christian [DK/DK]; (DK) (For US Only)
Inventors: NIELSEN, Claus Henrik; (DK).
ENEVOLD, Christian; (DK)
Agent: HØIBERG A/S; St. Kongensgade 59 A DK-1264 Copenhagen K (DK)
Priority Data:
PA 2010 70424 01.10.2010 DK
PA 2011 70182 15.04.2011 DK
Title (EN) GENETIC VARIATIONS IN THE INTERLEUKIN-6 RECEPTOR GENE AS PREDICTORS OF THE RESPONSE TO TREATMENT
(FR) VARIATIONS GÉNÉTIQUES DU GÈNE DU RÉCEPTEUR D'INTERLEUKINE-6 PERMETTANT DE PRÉDIRE LA RÉPONSE DE PATIENTS AU TRAITEMENT BASÉ SUR DES INHIBITEURS DUDIT RÉCEPTEUR D'INTERLEUKINE-6
Abstract: front page image
(EN)The present invention relates to a method for predicting the response of patients to treatment with lnterleukin-6 Receptor (IL6R) inhibitors, such as antibodies directed against the IL6R. The method comprises the analysis of one or more genetic variations, in particular single nucleotide polymorphisms, in or associated with the lnterleukin-6 Receptor gene,. The present invention further relates to a kit for use in predicting the response of patients to treatment with IL6R inhibitors, such as Tocilizumab. The patients suffers from rheumatoid arthritis.
(FR)Cette invention concerne une méthode permettant de prédire la réponse de patients à un traitement basé sur des inhibiteurs du récepteur d'interleukine-6 (IL6R), tels que des anticorps dirigés contre l'ILR6. La méthode comprend l'analyse d'une ou de plusieurs variations génétiques au sein du gène du récepteur d'interleukine-6 ou associées à celui-ci. Cette invention concerne, en outre, un kit destiné à être utilisé pour prédire la réponse de patients à un traitement basé sur lesdits inhibiteurs d'ILR6, tels que le Tocilizumab.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)